



RECEIVED
ATTENTION: BOX AFTER FINAL
AMENDMENT AND REPLY AFTER FINAL REJECTION UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
SEP 10 2002 EXAMINING GROUP 1616

TECH CENTER 1600/2900
Application No. 09/530,375
Attorney Docket No. 1142.0236-00
Customer No. 22,852

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Anthony ORMEROD et al.

Application No.: 09/530,375

Filed: July 7, 2000

For: SKIN PENETRATION
ENHANCING COMPONENTS

)
)
) Group Art Unit: 1616
)
) Examiner: M. Williamson
)
)
)
)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.116

In reply to the Office Action dated March 12, 2002, Applicants respectfully request reconsideration of this application in light of the following amendment and remarks. The period for response has been extended three months to September 12, 2002, by the accompanying petition and fee.

IN THE CLAIMS:

Please cancel claim 26 and amend claim 24 as follows:

24. (Twice Amended) A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic chosen from azithromycin or clarithromycin or an immunosuppressive macrolide chosen from sirolimus, FK506 or SDZ ASM 981, and a permeation modulator which are present in

↳ azithromycin

FINNEGAN
HERNDON
FARABOW
GARRETT &
DUNN LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com